Lenalidomide (Revlimid) + rituximab for relapsed/refractory follicular lymphoma and marginal zone lymphoma

featured image
Year: 2017

The drug combination of lenalidomide (oral capsules) and rituximab (by intravenous injection) has the potential to be an effective treatment for relapsed or refractory follicular and marginal zone lymphoma. The drug combination is being developed for patients that are eligible for rituximab monotherapy or for patients that need an alternative to standard chemotherapy regimens, where rituximab alone would be considered sub-optimal.